China Bozza Development Holdings Limited (HK:1069)
:1069
Top Page
China Bozza Development Holdings Limited
(1069)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.29
▼(-36.09% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial quality and high leverage risk, reinforced by bearish technicals with the stock trading below all major moving averages and negative MACD. The main offset is the very low P/E, but valuation support is limited without a dividend yield and given the operational and balance-sheet risks highlighted in the financial statements.
Positive Factors
Revenue Rebound
A clear revenue rebound through FY2025 indicates demand recovery and stronger top-line scale versus recent troughs. Sustained higher sales can support margin recovery, better fixed-cost absorption, and longer-term investments in operations, helping normalize profitability over the next 2–6 months.
Negative Factors
High Leverage
Very high leverage in an asset-heavy, cyclical industry materially increases refinancing, interest-rate, and liquidity risk. Even with some improvement, elevated debt burdens constrain capital allocation, raise financing costs, and make the company vulnerable if cash generation weakens or market conditions deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
A clear revenue rebound through FY2025 indicates demand recovery and stronger top-line scale versus recent troughs. Sustained higher sales can support margin recovery, better fixed-cost absorption, and longer-term investments in operations, helping normalize profitability over the next 2–6 months.
Read all positive factors
China Bozza Development Holdings Limited (1069) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$34.48M
Dividend YieldN/A
Average Volume (3M)417.79K
Price to Earnings (P/E)1.8
Beta (1Y)1.22
Revenue Growth88.72%
EPS Growth-91.59%
CountryHK
Employees33
SectorBasic Materials
Sector Strength58
IndustryPaper, Lumber & Forest Products
Share Statistics
EPS (TTM)0.06
Shares Outstanding102,924,220
10 Day Avg. Volume214,500
30 Day Avg. Volume417,794
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.30
Price to Sales (P/S)0.33
P/FCF Ratio-33.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Bozza Development Holdings Limited Business Overview & Revenue Model
Company Description
China Health Technology Group Holding Co., Ltd. is an investment company, which engages in the business of forestry management. It engages in the plantation, logging, and sale of timbre related products. The company was founded on October 8, 2009 ...
China Bozza Development Holdings Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
28
Negative
Cash Flow
52
Neutral
| Breakdown | TTM | Jun 2024 | Jun 2024 | Dec 2022 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.60M | 97.39M | 47.61M | 58.72M | 6.76M | 6.67M |
| Gross Profit | 8.62M | 8.87M | 1.90M | 11.51M | 0.00 | 6.67M |
| EBITDA | -7.74M | -7.74M | 208.39M | -42.17M | -9.85M | -48.36M |
| Net Income | 24.03M | 24.52M | 200.01M | -10.80M | -18.90M | -268.54M |
Balance Sheet | ||||||
| Total Assets | 225.04M | 191.09M | 178.17M | 140.64M | 93.52M | 491.54M |
| Cash, Cash Equivalents and Short-Term Investments | 4.92M | 2.68M | 3.23M | 4.33M | 1.11M | 134.00K |
| Total Debt | 127.45M | 115.23M | 119.11M | 356.77M | 321.97M | 333.44M |
| Total Liabilities | 173.86M | 166.22M | 165.20M | 457.35M | 400.15M | 369.48M |
| Stockholders Equity | 51.18M | 24.87M | 12.96M | -316.71M | -306.63M | 122.06M |
Cash Flow | ||||||
| Free Cash Flow | 1.77M | -959.71K | 28.63M | 22.16M | -466.00K | -5.58M |
| Operating Cash Flow | 1.77M | 37.43M | 28.86M | 23.44M | -466.00K | -5.58M |
| Investing Cash Flow | -6.15M | -38.34M | -26.49M | -23.26M | 2.00K | -410.00K |
| Financing Cash Flow | 3.83M | 2.29M | -3.47M | 3.04M | -249.00K | -3.29M |
China Bozza Development Holdings Limited Technical Analysis
Negative
0.46
Price Trends
0.39
Negative
0.42
Negative
0.43
Negative
Market Momentum
-0.02
Negative
34.67
Neutral
53.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1069, the sentiment is Negative. The current price of 0.46 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.39, and above the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 34.67 is Neutral, neither overbought nor oversold. The STOCH value of 53.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1069.
China Bozza Development Holdings Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$1.10B | 5.14 | 3.55% | 3.45% | -5.66% | -56.96% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
47 Neutral | HK$6.20B | -0.25 | ― | ― | -76.55% | -966.54% | |
47 Neutral | HK$79.46M | -2.98 | 0.85% | ― | -5.06% | ― | |
46 Neutral | HK$165.00M | 19.62 | 2.11% | 6.11% | 0.80% | 81.27% | |
45 Neutral | HK$396.09M | -4.13 | -37.51% | ― | -9.44% | ― | |
43 Neutral | HK$34.48M | 1.78 | 44.80% | ― | 88.72% | -91.59% |
* Basic Materials Sector Average
HK:1069
China Bozza Development Holdings Limited
0.34
-0.13
-27.17%
HK:1812
Shandong Chenming Paper Holdings Co., Ltd. Class H
1.11
0.58
109.43%
HK:2002
China Sunshine Paper Holdings Co. Ltd.
1.03
-0.84
-44.92%
HK:3363
Zhengye International Holdings Co., Ltd.
0.33
-0.04
-10.81%
HK:0731
C&D Newin Paper & Pulp Corporation Limited
0.28
0.08
36.59%
HK:0794
Come Sure Group (Holdings) Ltd.
0.24
0.06
33.33%
China Bozza Development Holdings Limited Corporate Events
China Health Technology Group Posts Modest Profit Growth on Higher Revenue
Feb 27, 2026
China Health Technology Group reported interim unaudited revenue of RMB34.4 million for the six months ended 31 December 2025, up from RMB31.1 million a year earlier, as gross profit rose to RMB4.1 million from RMB2.8 million. Profit for the perio...
China Health Technology Schedules Board Meeting to Review Interim Results and Dividend
Feb 12, 2026
China Health Technology Group Holding Company Limited has scheduled a board meeting for 27 February 2026. The board will review and approve the Group’s interim results for the six months ended 31 December 2025 and consider whether to declare...
China Health Technology Group bolsters board with two new director appointments
Jan 15, 2026
China Health Technology Group Holding Company Limited has strengthened its leadership team with the appointment of Ms. Cao Xiying as an executive director effective 15 January 2026, bringing project management and sales and marketing experience fr...
China Health Technology Details Board and Committee Structure
Jan 15, 2026
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors and the allocation of roles across its key governance committees. Chairman and CEO Ms. Bu Xue serves as an executive director, al...
China Health Technology Clarifies AGM Poll Results and Board Committee Heading
Jan 2, 2026
China Health Technology Group Holding Company Limited has issued a supplemental announcement correcting clerical errors in the disclosed poll results for two ordinary resolutions at its 31 December 2025 annual general meeting, specifically those r...
China Health Technology Wins Full Shareholder Backing for AGM Resolutions, New Share Scheme and Capital Mandates
Dec 31, 2025
Shareholders of China Health Technology Group Holding Company Limited approved all resolutions at the 31 December 2025 annual general meeting, including adoption of the 2025 financial statements, director remuneration, reappointment of Jon Gepsom ...
China Health Technology Group Sets Out Board and Committee Structure
Dec 31, 2025
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, naming Ms. Bu Xue as executive director, chairman and chief executive officer, alongside independent non-executive directors Mr....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.